SCHEMBL6325808

SCHEMBL6325808

COc1ccc(-c2cc(CCC(=O)O)no2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.62
ALDH1A1 P00352 5/20 0.62
HPGD P15428 2/20 0.62
RECQL P46063 1/20 0.62
RAB9A P51151 6/20 0.61
NPC1 O15118 5/20 0.61
SMN1; SMN2 Q16637 4/20 0.59
HTT P42858 2/20 0.59
KDM4E B2RXH2 1/20 0.58
PKM P14618 1/20 0.58
LMNA P02545 4/20 0.57
ATM Q13315 1/20 0.57
TP53 P04637 4/20 0.57
MEN1 O00255 3/20 0.57
TSHR P16473 3/20 0.57
KMT2A Q03164 3/20 0.57
CYP1A2 P05177 2/20 0.57
CYP3A4 P08684 2/20 0.57
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6333047 0.88 RAB9A (0.60) MAPTALDH1A1HPGDRECQLRAB9A
SCHEMBL20507192 0.82 NOTUM (0.63) MAPTALDH1A1HPGDRAB9ANPC1
SCHEMBL20507145 0.82 PTPN1 (0.59) MAPTALDH1A1HPGDRAB9ANPC1
SCHEMBL11902620 0.82 NPC1 (0.50) MAPTRAB9ANPC1SMN1; SMN2HTT
SCHEMBL8196656 0.80 NOTUM (0.64) MAPTALDH1A1HPGDRECQLRAB9A
SCHEMBL4544353 0.78 NPC1 (0.56) MAPTALDH1A1HPGDRECQLRAB9A
SCHEMBL1754915 0.77 NPC1 (0.55) MAPTALDH1A1HPGDRECQLRAB9A
SCHEMBL892240 0.77 HPGD (1.00) MAPTALDH1A1HPGDRECQLRAB9A
SCHEMBL2539999 0.77 NPC1 (0.55) MAPTALDH1A1HPGDRECQLRAB9A
SCHEMBL15094257 0.75 MAPT (0.56) MAPTALDH1A1HPGDRECQLRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 MAPT 729/4885ALDH1A1 338/4885HPGD 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.